William P Parker1, Philip L Ho2, Stephen A Boorjian1, Jonathan J Melquist2, Prabin Thapa1, Jeffrey M Holzbeierlein3, Igor Frank1, Ashish M Kamat2, Eugene K Lee4. 1. Department of Urology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. 2. Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Unit 1373, Houston, TX, 77030, USA. 3. Department of Urology, The University of Kansas Medical Center, 3901 Rainbow Blvd, MS 3016, Kansas City, KS, 66160, USA. 4. Department of Urology, The University of Kansas Medical Center, 3901 Rainbow Blvd, MS 3016, Kansas City, KS, 66160, USA. elee@kumc.edu.
Abstract
PURPOSE: Patients without evidence of disease at radical cystectomy (RC) following neoadjuvant chemotherapy (NAC) have the greatest potential for survival in muscle-invasive bladder cancer. Historically, 15 % of such patients will experience disease recurrence and cancer-specific mortality. We sought to evaluate the effect of pre-treatment clinical factors on the risk of recurrence in patients who were ypT0N0 at RC. METHODS: We performed a multi-institutional review of patients treated with NAC + RC for muscle-invasive bladder cancer (≥cT2) without pathologic evidence of disease at surgery (ypT0N0). The association of pre-treatment clinicopathologic features with recurrence was evaluated using Cox proportional hazards. RESULTS: A total of 78 patients were identified with ypT0 disease at RC after NAC. Median postoperative follow-up was 32.4 months (IQR 16.8, 60.0), during which time 17 patients recurred at a median of 6.4 months after RC. Estimated 3-year recurrence-free survival (RFS) of this cohort was 74.8 %. In univariate analysis, cT4 disease (HR 3.12; p = 0.04) and time to RC (HR 1.17 for each month increase; p < 0.01) were associated with inferior RFS. CONCLUSION: Patients without evidence of disease at the time of RC are still at risk of recurrence and death from bladder cancer. Higher clinical stage and increased time to RC were associated with an increased risk of recurrence and subsequent death. These data highlight the importance of timely RC and the continued risk of recurrence in higher clinically staged patients-underscoring the need for close monitoring and patient counseling.
PURPOSE:Patients without evidence of disease at radical cystectomy (RC) following neoadjuvant chemotherapy (NAC) have the greatest potential for survival in muscle-invasive bladder cancer. Historically, 15 % of such patients will experience disease recurrence and cancer-specific mortality. We sought to evaluate the effect of pre-treatment clinical factors on the risk of recurrence in patients who were ypT0N0 at RC. METHODS: We performed a multi-institutional review of patients treated with NAC + RC for muscle-invasive bladder cancer (≥cT2) without pathologic evidence of disease at surgery (ypT0N0). The association of pre-treatment clinicopathologic features with recurrence was evaluated using Cox proportional hazards. RESULTS: A total of 78 patients were identified with ypT0 disease at RC after NAC. Median postoperative follow-up was 32.4 months (IQR 16.8, 60.0), during which time 17 patients recurred at a median of 6.4 months after RC. Estimated 3-year recurrence-free survival (RFS) of this cohort was 74.8 %. In univariate analysis, cT4 disease (HR 3.12; p = 0.04) and time to RC (HR 1.17 for each month increase; p < 0.01) were associated with inferior RFS. CONCLUSION:Patients without evidence of disease at the time of RC are still at risk of recurrence and death from bladder cancer. Higher clinical stage and increased time to RC were associated with an increased risk of recurrence and subsequent death. These data highlight the importance of timely RC and the continued risk of recurrence in higher clinically staged patients-underscoring the need for close monitoring and patient counseling.
Authors: Andrew C James; Franklin C Lee; Jason P Izard; William P Harris; Heather H Cheng; Song Zhao; John L Gore; Daniel W Lin; Michael P Porter; Evan Y Yu; Jonathan L Wright Journal: Clin Genitourin Cancer Date: 2014-01-23 Impact factor: 2.872
Authors: Tobias Maurer; Michael Souvatzoglou; Hubert Kübler; Katharina Opercan; Stefan Schmidt; Ken Herrmann; Jens Stollfuss; Gregor Weirich; Bernhard Haller; Jürgen E Gschwend; Markus Schwaiger; Bernd J Krause; Uwe Treiber Journal: Eur Urol Date: 2011-12-14 Impact factor: 20.096
Authors: Stefan Tritschler; Clarissa Mosler; Julia Straub; Alexander Buchner; Alexander Karl; Anno Graser; Christian Stief; Derya Tilki Journal: World J Urol Date: 2011-12-25 Impact factor: 4.226
Authors: Wassim Kassouf; Philippe E Spiess; Gordon A Brown; Mark F Munsell; H Barton Grossman; Arlene Siefker-Radtke; Colin P N Dinney; Ashish M Kamat Journal: Eur Urol Date: 2007-04-10 Impact factor: 20.096
Authors: Robert S Svatek; Shahrokh F Shariat; Giacomo Novara; Eila C Skinner; Yves Fradet; Patrick J Bastian; Ashish M Kamat; Wassim Kassouf; Pierre I Karakiewicz; Hans-Martin Fritsche; Jonathan I Izawa; Derya Tilki; Vincenzo Ficarra; Bjoern G Volkmer; Hendrik Isbarn; Colin P Dinney Journal: BJU Int Date: 2011-01-18 Impact factor: 5.588
Authors: Peter E Clark; Neeraj Agarwal; Matthew C Biagioli; Mario A Eisenberger; Richard E Greenberg; Harry W Herr; Brant A Inman; Deborah A Kuban; Timothy M Kuzel; Subodh M Lele; Jeff Michalski; Lance C Pagliaro; Sumanta K Pal; Anthony Patterson; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Jerome P Richie; Wade J Sexton; William U Shipley; Eric J Small; Philippe E Spiess; Donald L Trump; Geoffrey Wile; Timothy G Wilson; Mary Dwyer; Maria Ho Journal: J Natl Compr Canc Netw Date: 2013-04-01 Impact factor: 11.908